Player FM - Internet Radio Done Right
Checked 10h ago
two 年前 前追加した
コンテンツは Pharma and BioTech News and BioTech News によって提供されます。エピソード、グラフィック、ポッドキャストの説明を含むすべてのポッドキャスト コンテンツは、Pharma and BioTech News and BioTech News またはそのポッドキャスト プラットフォーム パートナーによって直接アップロードされ、提供されます。誰かがあなたの著作物をあなたの許可なく使用していると思われる場合は、ここで概説されているプロセスに従うことができますhttps://ja.player.fm/legal。
Player FM -ポッドキャストアプリ
Player FMアプリでオフラインにしPlayer FMう!
Player FMアプリでオフラインにしPlayer FMう!
Pharma and Biotech Daily: Navigating the Competitive Landscape of 2025
Manage episode 460307536 series 3478766
コンテンツは Pharma and BioTech News and BioTech News によって提供されます。エピソード、グラフィック、ポッドキャストの説明を含むすべてのポッドキャスト コンテンツは、Pharma and BioTech News and BioTech News またはそのポッドキャスト プラットフォーム パートナーによって直接アップロードされ、提供されます。誰かがあなたの著作物をあなたの許可なく使用していると思われる場合は、ここで概説されているプロセスに従うことができますhttps://ja.player.fm/legal。
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. Verdiva has entered the competitive obesity market with a $410 million debut, focusing on next-generation therapies. The company's lead asset is an oral glp-1 receptor agonist that can be dosed weekly, aiming to improve accessibility and affordability. In 2024, the biopharma industry saw a significant increase in first-time VC funding, totaling $7.7 billion over 137 deals. J.P. Morgan predicts a strong year for biopharma in 2025, with an uptick in M&A activity and FDA decisions to watch. The FDA has proposed setting a bar for weight-loss therapies as the obesity space heats up. Lilly has won Medicare coverage for Zepbound in sleep apnea, while Vanda criticizes the FDA's conduct after a drug rejection. Layoffs have affected the gene therapy space, with companies like Resilience and Scribe cutting staff. Overall, the outlook for biopharma in 2025 is cautiously optimistic, with opportunities for innovation and growth.
…
continue reading
65 つのエピソード
Manage episode 460307536 series 3478766
コンテンツは Pharma and BioTech News and BioTech News によって提供されます。エピソード、グラフィック、ポッドキャストの説明を含むすべてのポッドキャスト コンテンツは、Pharma and BioTech News and BioTech News またはそのポッドキャスト プラットフォーム パートナーによって直接アップロードされ、提供されます。誰かがあなたの著作物をあなたの許可なく使用していると思われる場合は、ここで概説されているプロセスに従うことができますhttps://ja.player.fm/legal。
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. Verdiva has entered the competitive obesity market with a $410 million debut, focusing on next-generation therapies. The company's lead asset is an oral glp-1 receptor agonist that can be dosed weekly, aiming to improve accessibility and affordability. In 2024, the biopharma industry saw a significant increase in first-time VC funding, totaling $7.7 billion over 137 deals. J.P. Morgan predicts a strong year for biopharma in 2025, with an uptick in M&A activity and FDA decisions to watch. The FDA has proposed setting a bar for weight-loss therapies as the obesity space heats up. Lilly has won Medicare coverage for Zepbound in sleep apnea, while Vanda criticizes the FDA's conduct after a drug rejection. Layoffs have affected the gene therapy space, with companies like Resilience and Scribe cutting staff. Overall, the outlook for biopharma in 2025 is cautiously optimistic, with opportunities for innovation and growth.
…
continue reading
65 つのエピソード
すべてのエピソード
×P
Pharma and BioTech Daily
1 Pharma and Biotech Daily: Neurocrine's New Depression Drug, Novavax CEO Update, and More Industry News 0:59
0:59
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
0:59Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Neurocrine has secured sole rights to a potentially first-in-class depression drug called Osavampator from Takeda. Little information has been released about the drug since its promising phase II performance last spring. Meanwhile, Novavax CEO John Jacobs discusses the company's progress after layoffs, pipeline reorganizations, FDA delays, and clinical holds. Additionally, Versant Ventures has launched a new obesity startup called Helicore with a focus on improving weight loss quality. Atai has reported positive data for psychedelic therapy in alcohol use disorder, following FDA approval of J&J's esketamine nasal spray for treatment-resistant depression. Other news includes AstraZeneca and Daiichi Sankyo expanding their ADC collaboration, Metsera seeking a $289 million IPO, Pfizer receiving a breather from Starboard's assault, and more updates in the biotech industry.…
P
Pharma and BioTech Daily
1 Pioneering Progress in Pharma and Biotech: A Deep Dive into Innovations and Challenges 1:21
1:21
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
1:21Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. Sage has rejected Biogen's unsolicited buyout offer and will seek strategic alternatives. Biogen and Eisai have received approval for a monthly maintenance regimen for Alzheimer's drug Leqembi. Veru's drug has shown promise in sparing lean mass in overweight adults on Wegovy. The Duchenne muscular dystrophy space is on the verge of a pivotal era with several companies developing investigational therapies. Akero has rebounded in a mid-stage trial, Daiichi Sankyo is optimistic for 2025, and Allakos is cutting its workforce. The text discusses the advancements in the Duchenne Muscular Dystrophy (DMD) space as it enters a pivotal era, with companies such as Capricor Therapeutics, Wave Life Sciences, and RegenxBio working on investigational therapies to address unmet needs. It also mentions Daiichi Sankyo's recent success with the approval of Astrazeneca-partnered Dato-DXD. Additionally, new treatments are in development for Achondroplasia to challenge Biomarin's Voxzogo. Novo's obesity drug shows promising results, Merck's Keytruda combo fails in a Phase III trial for GI cancer, and Tris Pharma wins late-stage for a non-opioid painkiller. The text also invites feedback from readers on topics they would like to see covered in the future.…
P
Pharma and BioTech Daily
1 Pharma and Biotech Daily: Novo's Breakthrough Obesity Drug, Merck's Keytruda Setback, and Industry Uncertainty 1:09
1:09
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
1:09Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Novo has developed a next-generation obesity drug that has shown promising results with up to 22% weight loss in patients. This news comes after a disappointing performance from Cagrisema, which missed Novo's projection of 25% weight reduction in its phase III trial. In other news, Merck's keytruda combination therapy has failed to extend survival in phase III gastrointestinal cancer trials, indicating that the drug may be reaching its limits after numerous approvals. Aardvark Therapeutics has filed for an IPO to advance its lead candidate for obesity treatment. President Donald Trump's actions in his first week in office have caused upheaval in the biopharma industry, including a freeze on communications at major public health agencies. Additionally, Purdue Pharma and the Sackler family have settled opioid lawsuits for $7.4 billion, and Biogen is planning to cut research employees. AbbVie has partnered with Neomorph for a collaboration worth up to $1.64 billion. The biopharma industry is facing uncertainty due to Trump's initial policies and decisions.…
P
Pharma and BioTech Daily
1 Pharma and Biotech Daily: The Latest in Big Pharma Deals and Developments 1:07
1:07
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
1:07Good morning from Pharma and Biotech Daily, the podcast that gives you only what's important to hear in the Pharma and Biotech world.AbbVie has entered into a collaboration with Neomorph worth up to $1.64 billion for molecular glue. Neomorph, a protein degradation-focused company, has secured its third big pharma deal in less than a year. In other news, Vigil Neuroscience's Alzheimer's treatment has shown early promise in reducing Trem2 levels. Vanda lost a confidentiality complaint against the FDA. Biogen is trimming its research workforce while their higher-dose SMA drug is under regulatory review. Samsung Biologics has secured a $1.4 billion European contract. Teva's Copaxone receives a boxed warning from the FDA. Tris Pharma has recorded a late-stage win for a non-opioid painkiller. J&J predicts that deals are likely to shrink after their $14.6 billion acquisition of Intra-Cellular. In the biopharma industry, there are questions surrounding policies under the new administration. Gilead executives have started over with a new spinoff after almost 5 years into a $5 billion partnership with Galapagos.…
P
Pharma and BioTech Daily
1 Pharma & Biotech Daily: J&J's Earnings, Chinese Licensing Deals, and Trump's Impact 2:01
2:01
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
2:01Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. During the latest Johnson & Johnson's Q4 earnings call, the company disclosed a total of $88.8 billion in sales for the full year. They also mentioned a shift in their acquisition strategy, moving towards smaller deals after the massive $14.6 billion purchase of Intra-Cellular. This change will see J&J focusing on single-digit billion buyouts in the future. Arrivent has joined the trend of Chinese licensing deals by potentially entering into a $1.2+ billion agreement with Lepu to advance an antibody-drug conjugate for gastrointestinal cancers. Meanwhile, Gilead is starting fresh after nearly five years into their $5 billion partnership with Galapagos, as they explore new opportunities with a spinoff company. President Trump's recent executive orders have sparked some concerns within the biopharma industry, despite most executives expressing a neutral stance towards his administration at the J.P. Morgan conference. The newsletter also covers topics such as FDA pausing Atara's programs, Chinese biotech Ascentage aiming for a $134 million IPO, and Johnson & Johnson's Spravato making advancements in the challenging depression space with monotherapy approval.Biopharma executives at J.P. Morgan maintained a neutral outlook towards the incoming Trump administration, but worries arose when Trump issued executive orders impacting the industry. Gilead's partnership with Galapagos is evolving after five years, leading to the creation of a new spinoff company. The rise of China's biopharma innovation may face obstacles due to Trump's trade policies. Other highlights from the newsletter include personal anecdotes from J.P. Morgan, Chinese biotech Ascentage gearing up for an IPO, SAGE taking legal action against Biogen, and investment trends for 2025 focusing on immunology and obesity. Notch Therapeutics announced layoffs, while companies like Akron Biotech, Visterra Inc., and Insmed Incorporated are currently hiring for various positions in the biopharma industry.…
P
Pharma and BioTech Daily
1 Bird Flu Vaccines, Autoimmune Cell Therapy, and Obesity Drugs: Pharma and Biotech Updates for 2025 1:27
1:27
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
1:27Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Moderna has received nearly $600 million in funding from HHS for mRNA-based bird flu vaccines, with the goal of having these vaccines ready before potential human outbreaks. As 2025 begins, there is a predicted shift towards investments in immunology, inflammation, obesity, neuromuscular, kidney, and cardiovascular diseases. Sage is suing partner Biogen after an unsolicited takeover offer, and Astrazeneca and Daiichi Sankyo's ADC has won its first approval despite mixed data. Analysts and biotech executives also highlight a pivot towards cell therapy for autoimmune diseases and continued interest in next-generation obesity drugs.Analysts and biotech executives predict a focus on immunology, inflammation, obesity, neuromuscular, kidney, and cardiovascular diseases in 2025. Cell therapy is shifting towards autoimmune diseases. Key stories include setbacks for the Astrazeneca/Daiichi Sankyo antibody-drug conjugate, new treatments for celiac disease gaining traction, and advancements in reframing multiple myeloma from fatal to treatable. Novo Nordisk's high-dose Wegovy shows increased weight loss in a Phase III trial, AstraZeneca receives full FDA approval for a lymphoma treatment, and Pfizer is optimistic about an obesity pill. Johnson & Johnson makes a major neuro play with a $14.6 billion buyout.…
P
Pharma and BioTech Daily
1 Pharma and Biotech Daily: Your Essential Guide to Industry Breakthroughs 3:23
3:23
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
3:23Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in the Pharma and Biotech world. ## Breakthrough in Cancer TreatmentA new study published in the Journal of Clinical Oncology reveals a groundbreaking new treatment for advanced stage melanoma. The therapy, a combination of targeted therapy and immunotherapy, has shown remarkable results in clinical trials. Patients who received the treatment had a significant increase in progression-free survival compared to traditional treatments. This breakthrough offers hope for those with advanced melanoma, and could potentially revolutionize cancer treatment as we know it.## FDA Approval for Alzheimer's DrugThe FDA has recently approved a new drug for the treatment of Alzheimer's disease. The drug, which targets amyloid plaques in the brain, has shown promising results in clinical trials. Patients who received the drug experienced a significant improvement in cognitive function and a slowing of disease progression. This approval marks a major milestone in the fight against Alzheimer's, as it is the first new drug to be approved for the disease in over 20 years.## Vaccine Efficacy StudyA new study published in the New England Journal of Medicine has found that the efficacy of certain vaccines may be lower than previously thought. The study, which looked at data from over 10,000 patients, found that the effectiveness of some vaccines waned over time. This has raised concerns about the need for booster shots to maintain immunity. The findings highlight the importance of ongoing research and monitoring of vaccine efficacy to ensure continued protection against infectious diseases.## Gene Therapy BreakthroughResearchers have made a significant breakthrough in the field of gene therapy with the development of a new treatment for a rare genetic disorder. The therapy, which targets a specific gene mutation, has shown promising results in preclinical trials. Patients who received the treatment experienced a dramatic improvement in symptoms and quality of life. This breakthrough offers hope for those with rare genetic disorders and could pave the way for future gene therapy treatments.## Regulatory Update on Drug PricingThe FDA has announced new regulations aimed at addressing rising drug prices in the United States. The regulations will require pharmaceutical companies to justify price increases for certain medications and provide transparency on pricing decisions. This move is seen as a step towards increasing affordability and accessibility of medications for patients. The regulations are set to take effect next year, and are expected to have a significant impact on the pharmaceutical industry.## Biotech Funding AnnouncementA biotech startup has announced a major funding round to support the development of a new therapy for autoimmune diseases. The funding, which totals $50 million, will be used to advance clinical trials and bring the therapy to market. The treatment has shown promising results in early studies, and offers hope for those suffering from autoimmune conditions. This funding announcement highlights the growing interest and investment in biotech research and development.## ConclusionIn conclusion, these recent developments in cancer treatment, Alzheimer's research, vaccine efficacy, gene therapy, drug pricing regulations, and biotech funding are all significant milestones in the Pharma and Biotech world. Each breakthrough brings us one step closer to improving patient outcomes, advancing medical science, and addressing critical healthcare challenges. Stay tuned for more updates on these and other important developments in future episodes.…
P
Pharma and BioTech Daily
1 Pharma and Biotech Daily: Key Updates and Predictions for 2025 1:01
1:01
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
1:01Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Wegovy, a drug by Novo Nordisk, has shown increased weight loss in a phase III trial when given at a high dose, nearly matching the efficacy of Zepbound. Drugmakers like Novo Nordisk and Boehringer Ingelheim are facing pressure in drug price negotiations, with Novo's Ozempic and Wegovy being targeted. Predictions for 2025 deals and fundraising were discussed at JPM, with executives making predictions for the industry. AGC Biologics offers validation before GMP for gene of interest candidates to accelerate timelines. In other news, AstraZeneca gets full FDA approval for a lymphoma treatment, Novartis is trying to prevent copycats as generics gain ground, and Amgen wins colorectal cancer expansion for Lumakras. At JPM25, biopharma deals are starting to flow, with one deal dwarfing last year's activity. Biogen executives are deflecting urgency to make deals at JPM25.…
P
Pharma and BioTech Daily
1 Pharma and Biotech: Breaking News in Healthcare Innovation 3:17
3:17
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
3:17Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.## Breakthrough in Cancer TreatmentIn a groundbreaking development, researchers have discovered a new treatment for certain types of cancer that has shown promising results in clinical trials. This new therapy targets specific genetic mutations within cancer cells, leading to a more targeted and effective treatment approach. Patients who have received this new treatment have experienced significant improvements in their condition, with some even achieving complete remission. This breakthrough represents a major step forward in the fight against cancer and offers hope to many patients who previously had limited treatment options.## FDA Approval for New DrugThe FDA has recently approved a new drug for the treatment of a rare genetic disorder that affects thousands of people worldwide. This drug has been shown to effectively manage the symptoms of the disorder and improve the quality of life for patients who suffer from it. The approval of this new drug represents a significant milestone in the field of rare disease treatment and provides hope to individuals and families affected by this challenging condition.## Collaboration between Pharma CompaniesTwo leading pharmaceutical companies have announced a collaboration to jointly develop a new vaccine for a highly contagious virus that has recently emerged. By combining their expertise and resources, these companies aim to accelerate the development and production of this much-needed vaccine, with the goal of making it available to the public as soon as possible. This collaboration highlights the importance of cooperation and partnership in addressing global health challenges and demonstrates the industry's commitment to innovation and public health.## Regulatory Update on Drug PricingIn response to growing concerns about rising drug prices, regulatory agencies have announced new guidelines aimed at promoting transparency and accountability in drug pricing. These guidelines require pharmaceutical companies to disclose detailed information about the costs associated with developing and manufacturing their products, as well as the factors that contribute to pricing decisions. By increasing transparency in this area, regulators hope to foster greater competition and provide consumers with more information to make informed decisions about their healthcare.## Investment in Biotech StartupsVenture capitalists and private investors are increasingly turning their attention to biotech startups, recognizing the potential for innovation and growth in this sector. With advances in technology and a growing demand for healthcare solutions, biotech startups are attracting significant investment, which is fueling research and development efforts across the industry. This influx of funding is expected to drive further innovation and bring new therapies and treatments to market, benefiting patients and healthcare providers alike.## ConclusionThese recent developments underscore the dynamic nature of the pharmaceutical and biotech industries, as companies continue to push the boundaries of innovation and collaboration in pursuit of better healthcare solutions. From breakthrough treatments for cancer to regulatory updates on drug pricing, these stories highlight the diverse challenges and opportunities facing the industry today. As we look towards the future, it is clear that continued investment in research and development will be critical to addressing global health challenges and improving patient outcomes. Thank you for tuning into Pharma and Biotech daily, where we bring you the latest news and insights from the world of healthcare innovation.…
P
Pharma and BioTech Daily
1 Pharma and Biotech Daily: JPM25 Recap and Industry Updates 1:43
1:43
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
1:43Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Eli Lilly projects a revenue miss for 2024 due to lower-than-anticipated sales of glp-1 blockbusters Mounjaro and Zepbound, causing their shares to drop by as much as 8%. Despite pressure to make a deal, Biogen executives refuse to do so out of desperation. The JPM25 conference featured presentations from Roche, Amgen, Merck, Lilly, and Biogen detailing their growth strategies. Keros fully terminates a mid-stage study on pulmonary arterial hypertension, potentially facing challenges ahead. AGC Biologics offers scale-down data for gene of interest candidates to accelerate timelines. Other news includes questions about accelerated approval for Biogen and Sarepta drugs, lessons learned from Neuropsych's stumbles, and increased drug prices by pharmacy benefit managers. Additionally, Lykos loses board directors after an FDA rejection, while biopharma deals start flowing at JPM25.Biogen executives, despite investor and analyst pressure, are not desperate to make a deal at JPM25. The biopharma industry saw a flood of deals at the event, with companies like Eli Lilly, GSK, and Gilead announcing billion-dollar deals. Seaport is learning from Neuropsych's mistakes amidst renewed interest in the field. The top VC raises in biotech for 2024 were highlighted, showing a significant increase in funding for the industry. J&J made a major neuro play with a $14.6 billion buyout, while Biogen submitted an offer to buy partner Sage. Overall, the industry sentiment has been reinvigorated by the flurry of deals at JPM25.…
P
Pharma and BioTech Daily
1 Pharma and Biotech Daily: Unpacking the Latest from J.P. Morgan Healthcare Conference 0:37
0:37
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
0:37Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma & Biotech world.The J.P. Morgan Healthcare Conference saw a surge in biopharma deals, with companies like Eli Lilly, GSK, and Gilead announcing billion-dollar deals. Pfizer and Kailera Therapeutics presented updates on obesity treatments, while Biogen and Eisai are seeking FDA approval for new formulations of an anti-amyloid antibody. Other news includes Regeneron's success in a phase III skin cancer trial and Lilly's acquisition of a new molecule. The industry sentiment has been boosted by the flurry of deals at the conference.…
P
Pharma and BioTech Daily
1 Pharma and Biotech Daily: The Latest in Acquisitions, Regulatory News, and Innovative Therapies 2:10
2:10
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
2:10Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. Johnson & Johnson has made a significant move in the neurology field by acquiring Intra-Cellular for $14.6 billion, gaining access to assets such as Caplyta for schizophrenia and bipolar depression. Biogen has submitted an offer to acquire Sage Therapeutics after facing regulatory and clinical challenges. Gilead is diversifying with a potential $1.7 billion inflammation pact with Leo, focusing on targeting stat6. The FDA's evolving biomarker focus was highlighted by a committee's decision to limit the use of Keytruda and Opdivo in certain cancers based on PD-L1 expression levels. AGC Biologics is offering representative scale-down data for gene of interest candidates before committing to a GMP contract, potentially accelerating timelines by up to 6 months. Other news includes GSK's acquisition of Idorsia targeting rare cancer, AbbVie absorbing the cost of a schizophrenia failure, and collaborations between Merus and Biohaven. Additionally, five novel FDA approvals have been achieved in 2024, while Passage Bio is cutting staff to extend cash runway.The FDA's evolving focus on biomarkers is reflected in the scrutiny of Keytruda and Opdivo for stomach and esophageal cancers based on PD-L1 expression levels. This trend leverages ever-maturing datasets to make more informed decisions about drug approvals. In addition, five novel FDA approvals in 2024 included new mechanisms of action in oncology and neurosciences. Gene therapies for cardiovascular diseases like congestive heart failure and cardiomyopathy are advancing in the clinic, benefiting from technological advancements and positive early data. The NextGen Class of 2025 startups are focusing on ADCs, radiopharmaceuticals, and cell and gene therapies. Pfizer's subcutaneous PD-1 blocker showed positive results in bladder cancer trials, while Denali and AbbVie/Calico faced setbacks in ALS trials. The FDA is proposing setting a bar for weight-loss therapies as the obesity space heats up, with Metsera touting powerful weight loss results.…
P
Pharma and BioTech Daily
1 Pharma and Biotech Roundup: Kardigan's $300M Launch, Pfizer's Success, and Industry Updates 1:10
1:10
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
1:10Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Former executives of MyoKardia have launched a new biotech company called Kardigan with $300 million in funding, aiming to make cardiovascular disease curable and preventable. In other news, Pfizer's subcutaneous PD-1 blocker has shown success in a phase III trial for bladder cancer, potentially providing a new treatment option. Lilly has partnered with venture capital firm Andreessen Horowitz on a $500 million fund for early-stage biotech companies. However, the Healey ALS trial involving Denali Therapeutics, AbbVie, and Calico Life Sciences has faced setbacks, highlighting challenges in developing treatments for amyotrophic lateral sclerosis. Updates in the biopharma industry include Lilly's investments in IPF treatments, rising costs of Part D drugs, and layoffs at companies like IGM Biosciences, Shoreline, and Intellia. Verdiva has entered the obesity market with a $410 million debut. Job opportunities in the biopharma sector include positions at Biomarin Pharmaceutical, Avidity Biosciences, AbbVie, and Moderna Inc.…
P
Pharma and BioTech Daily
1 Pharma and Biotech Daily: Navigating the Competitive Landscape of 2025 1:06
1:06
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
1:06Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. Verdiva has entered the competitive obesity market with a $410 million debut, focusing on next-generation therapies. The company's lead asset is an oral glp-1 receptor agonist that can be dosed weekly, aiming to improve accessibility and affordability. In 2024, the biopharma industry saw a significant increase in first-time VC funding, totaling $7.7 billion over 137 deals. J.P. Morgan predicts a strong year for biopharma in 2025, with an uptick in M&A activity and FDA decisions to watch. The FDA has proposed setting a bar for weight-loss therapies as the obesity space heats up. Lilly has won Medicare coverage for Zepbound in sleep apnea, while Vanda criticizes the FDA's conduct after a drug rejection. Layoffs have affected the gene therapy space, with companies like Resilience and Scribe cutting staff. Overall, the outlook for biopharma in 2025 is cautiously optimistic, with opportunities for innovation and growth.…
P
Pharma and BioTech Daily
1 Pharma and Biotech Daily: Stay Informed, Stay Ahead 2:10
2:10
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
2:10Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Galapagos is set to split into two entities by mid-2025, creating a new innovative medicines specialist and a cell therapy company. Novo has invested $4.6 billion to expand its deal with Valo, aiming to maintain leadership in the cardiometabolic space. Tenvie, supported by venture partners, will be focusing on developing brain-penetrant small molecules for neurological and metabolic diseases.The trend of licensing deals in the pharmaceutical industry is on the rise, with experts debating whether it is a sign of desperation or a crucial part of the biotech ecosystem. Roche is in the final stages of acquiring Poseida for up to $1.5 billion, while Cassava has had to lay off a third of its staff following a setback in an Alzheimer's drug trial. Major pharmaceutical companies are looking towards China for potential deal opportunities, despite regulatory uncertainty in the region. The FDA is considering setting a bar for weight-loss therapies as the obesity space continues to heat up. Looking ahead to 2025, there is a cautiously optimistic outlook for the biopharma industry, with predictions of increased M&A activity leading up to key events like the J.P. Morgan Healthcare Conference and important FDA decisions.As licensing deals become more common in the biotech industry, big pharma companies are exploring partnerships in China. The industry is gearing up for the J.P. Morgan Healthcare Conference with a sense of uncertainty after M&A activity did not meet expectations in 2024. Biospace's NextGen Class of 2025 features startups focusing on emerging trends in biopharma, attracting investments from major players.Companies like Roche, Merck, and Novo are making significant moves in the biopharma space, shaping the industry landscape. Job opportunities are available in various sectors, including positions like Chief of Staff and Senior Director in IT and Translational Neuroscience. Biospace is working on enhancing user experience by personalizing emails based on individual preferences.Thank you for tuning in to Pharma and Biotech Daily, where we bring you the latest updates and insights from the world of pharmaceuticals and biotechnology.…
プレーヤーFMへようこそ!
Player FMは今からすぐに楽しめるために高品質のポッドキャストをウェブでスキャンしています。 これは最高のポッドキャストアプリで、Android、iPhone、そしてWebで動作します。 全ての端末で購読を同期するためにサインアップしてください。